{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:13:15Z","timestamp":1793236395852,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Estimated glomerular filtration rate (eGFR) predicts mortality and adverse cardiovascular events in people with chronic kidney disease. The significance of eGFR within the normal range and its long-term effect on clinical adverse events is unknown. We examined the effect of normal range or mildly reduced eGFR on long-term mortality in a large prospective registry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study included consecutive patients undergoing clinically-driven coronary angiography who had an eGFR \u226560 ml\/min\/1.73 m<jats:sup>2<\/jats:sup>. Baseline clinical characteristics were assessed, and patients were followed-up for the occurrence of all-cause mortality. Cox regression analysis was used to evaluate the impact of eGFR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 4186 patients were recruited. Median follow-up time was 2883 days (7.9 years). Mean age was 62.0 \u00b1 11.3 years with 77.4% males. Clinical presentation included acute coronary syndrome and stable angina. In a multivariable model adjusted for possible confounding factors, decreasing eGFR within the normal and mildly reduced range was inversely associated with long-term all-cause mortality with a hazard ratio (HR) of 1.32 for every decrease of 10 ml\/min\/1.73<jats:sup>2<\/jats:sup> in eGFR. Compared to eGFR &gt; 100 ml\/min\/1.73<jats:sup>2<\/jats:sup>, there was a graded association between lower eGFR values and increased long term mortality with a HR of 1.16 (0.59\u20132.31) for eGFR 90\u2013100 ml\/min\/1.73<jats:sup>2<\/jats:sup>, HR 1.54 (0.81\u20132.91) for eGFR 80\u201390 ml\/min\/1.73<jats:sup>2<\/jats:sup>, HR 2.62 (1.41\u20134.85) for eGFR 70\u201380 ml\/min\/1.73<jats:sup>2<\/jats:sup> and HR 2.93 (1.58\u20135.41) for eGFR 60\u201370 ml\/min\/1.73<jats:sup>2<\/jats:sup>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>eGFR within the normal and mildly reduced range is an independent predictor of long-term all-cause mortality in selected patients undergoing clinically driven coronary angiography.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000985","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T01:16:18Z","timestamp":1606180578000},"page":"302-308","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The impact of normal range estimated glomerular filtration rate on mortality in selected patients undergoing coronary angiography \u2013 a long-term follow-up"],"prefix":"10.1097","volume":"32","author":[{"given":"Lior","family":"Zornitzki","sequence":"first","affiliation":[{"name":"Cardiology"},{"name":"Internal Medicine B"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapir","family":"Sadon","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atalia","family":"Wenkert","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Steinvil","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maayan","family":"Konigstein","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ben-Shoshan","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Kliuk-Ben Bassat","sequence":"additional","affiliation":[{"name":"Nephrology, Tel Aviv Sourasky Medical Center, Affiliated With Sackler School of Medicine, Tel Aviv University, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Sirota","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Halkin","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bazan","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Banai","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Arbel","sequence":"additional","affiliation":[{"name":"Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1093\/eurheartj\/ehw378","article-title":"Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease.","volume":"37","author":"Baber","year":"2016","journal-title":"Eur Heart J"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"e0221044","DOI":"10.1371\/journal.pone.0221044","article-title":"Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status.","volume":"14","author":"Currie","year":"2019","journal-title":"PLoS One"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","article-title":"Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.","volume":"41","author":"Manjunath","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250729","first-page":"1374","article-title":"Impact of estimated glomerular filtration rate on vascular disease extent and adverse cardiovascular events in patients without chronic kidney disease.","volume":"29","author":"Arbel","year":"2013","journal-title":"Can J Cardiol"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jdiacomp.2015.04.004","article-title":"Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.","volume":"29","author":"von Scholten","year":"2015","journal-title":"J Diabetes Complications"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00392-013-0641-7","article-title":"Admission glucose, fasting glucose, HbA1c levels and the SYNTAX score in non-diabetic patients undergoing coronary angiography.","volume":"103","author":"Arbel","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000444008","article-title":"HbA1c levels and long-term mortality in patients undergoing coronary angiography.","volume":"134","author":"Havakuk","year":"2016","journal-title":"Cardiology"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2020.10.004","article-title":"Blood acetylcholinesterase activity is associated with increased 10 year all-cause mortality following coronary angiography.","volume":"313","author":"Shenhar-Tsarfaty","year":"2020","journal-title":"Atherosclerosis"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R12-20250729","first-page":"1","article-title":"International Society of Nephrology. Notice.","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"e010596","DOI":"10.1161\/JAHA.118.010596","article-title":"Change of kidney function is associated with all","volume":"7","author":"Guo","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.chest.2018.05.017","article-title":"Left atrial volume as a biomarker of target organ damage in cardionephrology: a study in a wide range of renal function.","volume":"154","author":"Rozenbaum","year":"2018","journal-title":"Chest"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/archinte.166.17.1884","article-title":"Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.","volume":"166","author":"Parikh","year":"2006","journal-title":"Arch Intern Med"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A randomized trial of dietary sodium restriction in CKD.","volume":"24","author":"McMahon","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.ajkd.2011.10.008","article-title":"Exercise in individuals with CKD.","volume":"59","author":"Johansen","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1159\/000489913","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis.","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehr035","article-title":"Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients.","volume":"32","author":"Mills","year":"2011","journal-title":"Eur Heart J"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjmed.2007.10.002","article-title":"Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.","volume":"121","author":"Berger","year":"2008","journal-title":"Am J Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:07:57Z","timestamp":1753812477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000985","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}